1 in 5 insulin users on Medicare has ‘catastrophic’ drug spending, Yale finds. The Inflation Reduction Act may help

Senate passed bill limiting out-of-pocket spending on insulin to $35 per month for Medicare beneficiaries. Other patients still face high costs for treatment.